INTERNAL DISCOVERY PROGRAMS

Targeting near-to-market and in-market drugs with known liabilities, where our chemical modification capabilities can be applied to generate enhanced product candidates

In conjunction with leading clinical advisors, Anthill has initiated programs based on an in-market anti-inflammatory class of drugs and on a clinical-stage glaucoma candidate